

House File 2140 - Introduced

HOUSE FILE 2140

BY A. MEYER

A BILL FOR

1 An Act relating to patient education prior to the prescription
2 of an opioid.

3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

1 Section 1. NEW SECTION. 124.559 Provision of information —
2 prescribing of controlled substances for acute or chronic pain.

3 1. Prior to issuing an initial prescription for a schedule
4 II controlled substance or any other prescription opioid in a
5 course of treatment for acute or chronic pain, and again prior
6 to issuing the third prescription in the course of treatment,
7 a prescribing practitioner shall discuss with the patient,
8 or the patient's parent or guardian if the patient is under
9 eighteen years of age and is not an emancipated minor, the
10 risks associated with the substance being prescribed, including
11 but not limited to:

12 a. The risks of addiction and overdose associated with
13 opioid drugs and the dangers of taking opioid drugs with
14 alcohol, benzodiazepines, and other central nervous system
15 depressants.

16 b. The reasons why the prescription is necessary.

17 c. Alternative treatments that may be available.

18 d. The risks associated with the use of the substance
19 being prescribed, specifically that opioids are highly
20 addictive, even when taken as prescribed, that there is a
21 risk of developing a physical or psychological dependence on
22 the substance and that the risks of taking more opioids than
23 prescribed, or mixing sedatives, benzodiazepines or alcohol
24 with opioids, can result in fatal respiratory depression.

25 e. The dangers and risks of use of the substance to persons
26 other than the patient using the substance. The prescribing
27 practitioner shall advise the patient to keep the substance in
28 a locked container.

29 2. The prescribing practitioner shall include a note
30 in the patient's medical record that the patient or the
31 patient's parent or guardian, as applicable, has discussed
32 with the practitioner the risks of developing a physical or
33 psychological dependence on the prescribed substance and
34 alternative treatments that may be available.

35 3. This section shall not apply to a prescription for the

1 substances specified for a patient who is currently in active
2 treatment for cancer or receiving hospice or palliative care
3 through a hospice program as defined in section 135J.1, for the
4 resident of a long-term care facility, or to any substances
5 that are being prescribed for use in the treatment of substance
6 use disorder or opioid dependence.

7 4. As used in this section:

8 a. *"Long-term care facility"* means the same as defined in
9 section 231.4.

10 b. *"Prescribing practitioner"* means the same as defined in
11 section 124.550.

12 Sec. 2. CODE EDITOR DIRECTIVE. The Code editor shall
13 designate section 124.559, as enacted in this Act, as a new
14 subchapter within chapter 124.

15 EXPLANATION

16 The inclusion of this explanation does not constitute agreement with
17 the explanation's substance by the members of the general assembly.

18 This bill relates to the information to be provided by a
19 prescribing practitioner to a patient prior to the prescribing
20 of a controlled substance for acute or chronic pain. The bill
21 provides that prior to issuing an initial prescription of a
22 schedule II controlled substance or any other prescription
23 opioid in a course of treatment for acute or chronic pain, and
24 again prior to issuing the third prescription in the course of
25 treatment, a prescribing practitioner shall discuss with the
26 patient, or the patient's parent or guardian if the patient
27 is under 18 years of age and is not an emancipated minor, the
28 risks associated with the substance being prescribed. The
29 information to be discussed includes but is not limited to:
30 the risks of addiction and overdose associated with opioid
31 drugs and the dangers of taking opioid drugs with alcohol,
32 benzodiazepines, and other central nervous system depressants;
33 the reasons why the prescription is necessary; alternative
34 treatments that may be available; the risks associated with
35 the use of the substance being prescribed; and the dangers

1 and risks of use of the substance by persons other than the
2 patient. The prescribing practitioner shall include a note
3 in the patient's medical record that the patient or the
4 patient's parent or guardian, as applicable, has discussed
5 with the practitioner the risks of developing a physical or
6 psychological dependence on the prescribed substance and
7 alternative treatments that may be available. The bill does
8 not apply to a prescription for the substances specified in
9 the bill for a patient who is currently in active treatment
10 for cancer or receiving hospice or palliative care through a
11 hospice program, for the resident of a long-term care facility,
12 or to any substances that are being prescribed for use in the
13 treatment of substance use disorder or opioid dependence.